Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt.

Cancer research - 15 Jun 2007

Yamasaki Fumiyuki, Johansen Mary J, Zhang Dongwei, Krishnamurthy Savitri, Felix Edward, Bartholomeusz Chandra, Aguilar Richard J, Kurisu Kaoru, Mills Gordon B, Hortobagyi Gabriel N, Ueno Naoto T

Abstract excerpt

Erlotinib (Tarceva), an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has clinical activity in advanced lung cancer, but disease that initially responds to erlotinib eventually progresses. The mechanism of this acquired resistance is unclear. We established two erlotinib-resi...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chromatography, Liquid
Share to Erlotinib Hydrochloride

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Dosage

Share to Immunoprecipitation

Share to Mass Spectrometry

Share to Proto-Oncogene Proteins c-akt

Share to PTEN Phosphohydrolase

Share to Quinazolines

Source

Identifiers

PMID: 17575145
DOI: 10.1158/0008-5472.CAN-06-3020

Genes

EGFR
PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-17575145-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt.PMID 17575145Read ↗

MAP2K1 is a potential therapeutic target in erlotinib resistant head and neck squamous cell carcinoma.Semantic proximity Read ↗

The insulin-like growth factor 1 receptor causes acquired resistance to erlotinib in lung cancer cells with the wild-type epidermal growth factor receptor.Semantic proximity Read ↗

Modeling acquired TKI resistance and effective combination therapeutic strategies in murine RET+ lung adenocarcinomaSemantic proximity Read ↗

JAK2-related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor-activating mutation.Semantic proximity Read ↗

Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.Semantic proximity Read ↗

Overcoming resistance to tyrosine kinase inhibitors: Lessons learned from cancer cells treated with EGFR antagonistsSemantic proximity Read ↗

Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib.Semantic proximity Read ↗

<i>PTEN</i> Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFRSemantic proximity Read ↗

High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886).Semantic proximity Read ↗

PAK1 Is a Novel Therapeutic Target in Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma Activated by the PI3K/AKT Signaling Regardless of EGFR Mutation.Semantic proximity Read ↗

Erlotinib and Trametinib in Patients With EGFR-Mutant Lung Adenocarcinoma and Acquired Resistance to a Prior Tyrosine Kinase Inhibitor.Semantic proximity Read ↗

PPP3CB overexpression mediates EGFR TKI resistance in lung tumors via calcineurin/MEK/ERK signaling.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.